Related Experiment Video

Updated: Aug 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Polymorphism of the type 6 adenylyl cyclase gene and cardiac hypertrophy

Eiko Ikoma1, Takashi Tsunematsu, Ichirou Nakazawa

  • 1Department of Physiology, Yokohama City University School of Medicine, Yokohama, Japan.

Journal of Cardiovascular Pharmacology
|February 12, 2004
PubMed

Insights

Genetic variations in the type 6 adenylyl cyclase gene were studied for links to left ventricular hypertrophy. The AA genotype may increase risk for this heart condition, independent of blood pressure.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Human Genetics

Background:

  • Type 6 adenylyl cyclase is a key cardiac isoform regulating heart function.
  • Genetic variations in this enzyme may influence cardiovascular health.
  • Left ventricular hypertrophy is a significant risk factor for heart disease.

Purpose of the Study:

  • To investigate the association between type 6 adenylyl cyclase gene polymorphism and left ventricular hypertrophy in a Japanese population.
  • To identify potential genetic risk factors for left ventricular hypertrophy.

Main Methods:

  • Genotyping of type 6 adenylyl cyclase gene single nucleotide polymorphism (T11215A) using mutagenically separated polymerase chain reaction.
  • Analysis of 2068 subjects undergoing cardiovascular disease health screening.
  • Statistical analysis of genotype frequencies and left ventricular hypertrophy, considering blood pressure.

Main Results:

  • No significant association was found between left ventricular hypertrophy and type 6 adenylyl cyclase gene polymorphism overall.
  • Left ventricular hypertrophy was associated with increased blood pressure in TT and TA genotype groups.
  • The AA genotype group showed no association between left ventricular hypertrophy and increased blood pressure.

Conclusions:

  • The AA genotype of the type 6 adenylyl cyclase gene may confer an independent risk for developing left ventricular hypertrophy.
  • Further research is needed to elucidate the mechanisms underlying this association.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...